Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Non-ANCA Leucocytoclasic Vasculitis Induced by Sofosbuvir/Ledipasvir Treatment: A Case Report

Author(s): Yosra Zaimi, Myriam Ayari*, Nadine Ghithia and Shema Ayadi

Volume 19, Issue 1, 2024

Published on: 28 April, 2023

Page: [145 - 147] Pages: 3

DOI: 10.2174/1574886318666230406083939

Price: $65

Abstract

Background: The development of direct-acting antivirals directed against the Hepatitis C Virus has dramatically modified the therapeutic approach to chronic hepatic viral disease. Larger use of such drugs has also led to increasing reports about their adverse effects. This report aimed to describe a case of leucocytoclasic vasculitis following treatment based on the sofosbuvir/ledipasvir regimen with complete disappearance shortly after withdrawal in a 61-year-old patient treated for genotype 1 hepatitis C.

Case Presentation: A 61-year-old Tunisian woman with a history of hepatitis C virus genotype 1 infection developed palpable purpura in front of low extremity articulation, five weeks after the onset of sofosbuvir/Ledipasvir. The histological examination concluded with leucocytoclasic vasculitis, with total disappearance three days after withdrawal. The pre-therapeutic assessment showed no positivity of Cryoglobulinemia. Anti-neutrophil cytoplasmic antibodies (ANCA) were negative. A sustained viral response was obtained only 5 weeks after treatment without an increase of viral load during follow-up.

Conclusion: There was a temporal relationship between antiviral treatment and non-ANCA skin vasculitis. The pharmacological department concluded the imputability of antiviral treatment (score I2B2).

Keywords: Leucocytoclasic vasculitis, direct-acting antivirals, hepatitis C, drug adverse effect, sofosbuvir/ledipasvir, ANCA.

« Previous Next »
Graphical Abstract

[1]
McGlynn EA, Adams JL, Kramer J, et al. Assessing the safety of direct-acting antiviral agents for hepatitis C. JAMA Netw Open 2019; 2(6): e194765.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.4765] [PMID: 31173117]
[2]
Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65(1): 1-11.
[http://dx.doi.org/10.1002/art.37715] [PMID: 23045170]
[3]
Shavit E, Alavi A, Sibbald RG. Vasculitis-what do we have to know? A review of literature. Int J Low Extrem Wounds 2018; 17(4): 218-26.
[http://dx.doi.org/10.1177/1534734618804982] [PMID: 30501545]
[4]
Antiga E, Verdelli A, Bonciani D, et al. Drug-induced cutaneous vasculitides. G Ital Dermatol Venereol 2015; 150(2): 203-10.
[PMID: 25776141]
[5]
Yaseen K, Nevares A, Tamaki H. A spotlight on drug-induced vasculitis. Curr Rheumatol Rep 2022; 24(11): 323-36.
[http://dx.doi.org/10.1007/s11926-022-01088-0] [PMID: 36129631]
[6]
Fekete GL, Fekete L. Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature. Exp Ther Med 2019; 17(2): 1128-31.
[PMID: 30679984]
[7]
Stokes W, Fenton C, Clement F, James M, Ronksley P, Tang KL. The efficacy and safety of 12 weeks of sofosbuvir and ledipasvir versus sofosbuvir, ledipasvir and ribavirine in patients with chronic hepatitis C, genotype 1, who have cirrhosis and have failed prior therapy: A systematic review and meta-analysis. Can J Gastroenterol Hepatol 2017; 2017: 1-8.
[http://dx.doi.org/10.1155/2017/6468309] [PMID: 28367429]
[8]
Gadde S, Lee B, Kidd L, Zhang R. Antineutrophil cytoplasmic antibodies crescentic allograft glomerulonephritis after sofosbuvir therapy. World J Nephrol 2016; 5: 547-0.
[http://dx.doi.org/10.5527/wjn.v5.i6.547]
[9]
Ahmad YK, Tawfeek S, Sharaf-Eldin M, et al. Antinuclear cytoplasmic antibody-associated Vasculitis: A probable adverse effect of Sofosbuvir treatment in chronic hepatitis C patients. Hosp Pharm 2017; 52: 294-301.
[http://dx.doi.org/10.1310/hpj5204-294]
[10]
Campione E, Dattola A, Di Prete M, et al. Sofosbuvir induced leucocytoclasic vasculitis: A case report. BMC Dermatol 2019; 19(1): 6.
[http://dx.doi.org/10.1186/s12895-019-0086-4] [PMID: 31096980]

Rights & Permissions Print Cite
Article Metrics
6
1
© 2024 Bentham Science Publishers | Privacy Policy